Study on the Effect of Combined Treatment of HFHD and Hemoperfusion Therapy on Patients with End-Stage Renal Disease
Objective Study on the effect of combination therapy of high flux hemodialysis(HFHD)and hemoperfusion(HP)on patients with end-stage renal disease(ESRD).Methods Fifty-two ESRD patients admitted to our hospital from May 2022 to August 2023 were selected as the research subjects,randomly divided into an experimental group and a control group,with 26 cases in each group.The control group received HFHD treatment,while the experimental group received HP treatment on the basis of the control group.Compare the levels of micro inflammation,renal function indicators,and calcium and phosphorus metabolism between two groups.Results The levels of serum amyloid A,interleukin-6,tumor necrosis factor alpha,and transforming growth factor-β1 in the experimental group were all lower than those in the control group,the differences between groups were statistically significant(P＜0.05).The levels of serum creatinine,blood urea nitrogen,and β2 microglobulin in the experimental group were lower than those in the control group,the differences between groups were statistically significant(P＜0.05).The levels of phosphorus,alkaline phosphatase,and serum intact parathyroid hormone in the experimental group were lower than those in the control group,while the levels of calcium were higher than those in the control group,the differences between groups were statistically significant(P＜0.05).Conclusion The combination therapy of HFHD and HP can improve renal function indicators,reduce micro inflammation levels,and restore calcium and phosphorus metabolism levels in ESRD patients.
End-stage renal diseaseHigh flux hemodialysisHemoperfusionCalcium and phosphorus metabolism levelsRenal function
NETL
NSTL
万方数据
